PMID- 31359441
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20211204
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 91
IP  - 12
DP  - 2019 Dec
TI  - Ginkgo biloba extract may alleviate viral myocarditis by suppression of S100A4 
      and MMP-3.
PG  - 2083-2092
LID - 10.1002/jmv.25558 [doi]
AB  - Viral myocarditis (VMC) is an inflammatory cardiac disease caused by 
      coxsackievirus B3 (CVB3) that leads to heart failure or sudden death. However, 
      efficient therapeutic strategies for VMC remain lacking. Ginkgo biloba extract 
      was previously demonstrated to have anti-inflammatory activity and had been used 
      in prevention and therapy of some cardiovascular diseases (ie myocardial 
      infarction), indicating Ginkgo biloba extract may be a potential drug for the 
      treatment of VMC. This study was, for the first time, to investigate the 
      intervention effects of Ginkgo biloba extract on VMC model mice and explore its 
      potential mechanisms. As a result, VMC mice model was successfully established by 
      CVB3 infection, exhibiting significantly higher viral titer, serum creatine 
      kinase isoenzyme level, heart weight/body weight ratio, histopathologic scores, 
      collagen volume fraction (CVF), and significantly increased expression of S100A4 
      and matrix metalloproteinase-3 (MMP-3) at protein and messenger RNA levels 
      compared with the control group. Also, the expression of S100A4 and MMP-3/CVF was 
      positively correlated. Ginkgo biloba extract treatment significantly reversed the 
      trend in all the above parameters. Thus, Ginkgo biloba extract may be a promising 
      therapeutic approach against VMC because it improved myocardial injury and 
      alleviated the degree of myocardial fibrosis through suppression of S100A4 and 
      MMP-3.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Wang, Wei
AU  - Wang W
AD  - Outpatient Department of Pediatrics, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
FAU - Ma, Ke
AU  - Ma K
AD  - Outpatient Department of Pediatrics, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
FAU - Liu, Jiangtao
AU  - Liu J
AD  - Outpatient Department of Pediatrics, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
FAU - Li, Feng
AU  - Li F
AUID- ORCID: 0000-0001-5790-1246
AD  - Outpatient Department of Pediatrics, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
LA  - eng
PT  - Journal Article
DEP - 20190809
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Plant Extracts)
RN  - 0 (S100 Calcium-Binding Protein A4)
RN  - 0 (S100a4 protein, mouse)
RN  - 19FUJ2C58T (Ginkgo biloba extract)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.17 (Mmp3 protein, mouse)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Coxsackievirus Infections/drug therapy
MH  - Enterovirus B, Human/*drug effects
MH  - Ginkgo biloba
MH  - Male
MH  - Matrix Metalloproteinase 3
MH  - Matrix Metalloproteinase Inhibitors/*therapeutic use
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Myocarditis/*drug therapy/virology
MH  - Plant Extracts/*therapeutic use
MH  - S100 Calcium-Binding Protein A4/*antagonists & inhibitors
OTO - NOTNLM
OT  - coxsackievirus
OT  - gene expression
OT  - inflammation
EDAT- 2019/07/31 06:00
MHDA- 2020/07/16 06:00
CRDT- 2019/07/31 06:00
PHST- 2018/11/22 00:00 [received]
PHST- 2019/06/25 00:00 [accepted]
PHST- 2019/07/31 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2019/07/31 06:00 [entrez]
AID - 10.1002/jmv.25558 [doi]
PST - ppublish
SO  - J Med Virol. 2019 Dec;91(12):2083-2092. doi: 10.1002/jmv.25558. Epub 2019 Aug 9.